A5103057705- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Cutaneous lymphoproliferative disorders research
- Allergic Rhinitis and Sensitization
- Urticaria and Related Conditions
- Asthma and respiratory diseases
- Lymphoma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- T-cell and Retrovirus Studies
- Nail Diseases and Treatments
- Pharmaceutical studies and practices
- Autoimmune and Inflammatory Disorders Research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Systemic Lupus Erythematosus Research
- Immune Response and Inflammation
- Cytokine Signaling Pathways and Interactions
- Inflammasome and immune disorders
- Fungal Infections and Studies
- Immune cells in cancer
- CAR-T cell therapy research
- Complementary and Alternative Medicine Studies
- Autoimmune and Inflammatory Disorders
- Contact Dermatitis and Allergies
- Medicine and Dermatology Studies History
Zentralklinik Bad Berka
2018-2024
Medical University of Graz
2021
Joanneum Research
2021
Dr. Reddy's Laboratories (Switzerland)
2021
Dr. Reddy's Laboratories (United States)
2021
University Hospital Münster
2008-2020
University of Münster
2008-2019
Universitätsmedizin Greifswald
2007-2016
Hautklinik Heidelberg
2011
Universität Hamburg
2005-2008
Abstract Glucocorticoids (GC) are still the most widely used immunosuppressive agents in clinical medicine. Surprisingly, little is known about mechanisms of GC action on monocytes, although these cells exert pro- and anti-inflammatory effects. We have shown recently that induce a specific monocyte phenotype with properties humans. now investigated whether this also applies for murine system how subset would relate to defined subtypes. After treatment dexamethasone 48 h, monocytes...
Secukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various psoriatic disease manifestations adults.Here, the and of two secukinumab dosing regimens [low dose (LD) high (HD)] paediatric patients severe chronic plaque psoriasis over one year are reported.In this multicentre, double-blind study (NCT02471144), aged 6 to <18 years were stratified randomized by weight (<25 kg, 25 <50 ≥50 kg) age (6 <12 years, 12 years) receive low-dose (LD: 75/75/150 mg)...
Dupilumab, a human anti-interleukin-4 receptor alpha monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate-to-severe atopic dermatitis randomized, double-blind, placebo-controlled, phase IIa trial.We evaluate health-related quality of life (HRQoL) correlation HRQoL secondary patient-reported outcomes subset patients from this trial dupilumab.Patients were randomized to 300 mg weekly subcutaneous dupilumab or placebo for 12 weeks (trial registration:...
The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus nodular prurigo. Patients were randomized receive either first oral 80 mg/day or for 4 weeks. Following a 2-week wash-out phase, crossed-over other treatment Primary efficacy criterion intra-individual difference between mean itch intensity (visual analogue scale) at...
Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A.To assess the efficacy safety of different maintenance dosing regimens secukinumab 300 mg based on Psoriasis Area Severity Index (PASI) response at week 24 in patients with moderate-to-severe plaque psoriasis.OPTIMISE was randomized, open-label, rater-blinded phase IIIb study. Patients (n = 1647) received baseline; weeks 1, 2, 3 4; every 4 (q4w) 24. At 24, PASI 90 responders (≥ 90%...
Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) an IL-23 inhibitor licensed for moderate-to-severe plaque psoriasis. Regulatory approval medicinal products based on safety efficacy data from randomized controlled trials (RCTs) which impose stringent selection criteria. Long-term non-interventional studies (NIS) are needed to establish effectiveness in daily practice bridging gap between RCTs real-world setting.This...
Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or 'plus' and eudermic cleansers for all patients improve the skin barrier provide anti-irritant anti-pruritic effects.To investigate efficacy of care (in addition treatment) with an Emollient balm designed microbiome plus a corresponding syndet compared usual commercial cleansers.In randomized controlled multicenter study, moderate (Severity scoring atopic dermatitis...
Currently valid itch intensity scales, such as the visual analogue scale (VAS), are indispensable, but they can be influenced by patient?s overall health status. The aim of this study was to evaluate reliability and validity Dynamic Pruritus Score (DPS), a new instrument comparing reduction in current pruritus with defined earlier time-point. Eighty-one randomly selected adults (50 females, mean age 53.9 years) recorded their at visit 1 repeatedly 2 on DPS, VAS, numerical rating scale,...
The impact of dermatological diseases goes beyond symptoms and often includes psychosocial burden. Self-stigmatization plays a key role in this relationship was compared patients with psoriasis atopic dermatitis to evaluate the validity cross-disease stigmatization models. In total, 101 per indication were included cross-sectional study. Besides sociodemographic clinical data, patient-reported outcome measures relating self-stigmatization, depression, anxiety, quality life across groups....
Involvement of the scalp is common in psoriasis and severely affects quality life those affected. It difficult to treat places special demands on galenics a drug formulation. Tacrolimus calcineurin inhibitor approved as an ointment formulation for treatment atopic dermatitis. The efficacy safety topically applied tacrolimus have also been studied proven psoriasis. However, no proprietary pharmaceutical product currently this indication. A multicenter, double-blind, vehicle-controlled phase 3...
Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in treatment various entities malignant tumors. Patients treated with EGFR inhibitors very likely develop cutaneous side effects. The development a papulopustular, follicular exanthema during first weeks therapy correlates therapeutic benefit. However, this and other effects can impair quality life patient might limit inhibitor. For an optimal benefit adequate management is necessary. A panel German...
Abstract Objective The aim of this study was to evaluate the safety and efficacy profile pegylated interferon α‐2b (PEG‐IFN α‐2b) in combination with photochemotherapy (PUVA) treatment cutaneous T‐cell lymphoma (CTCL) comparison standard IFN α plus PUVA. Design Retrospective cohort over a period 7 years. Patients interventions A total 17 consecutive CTCL patients (stage IA–IV) were retrospectively analysed for toxicity response rates associated PEG‐IFN (1.5 μg/kg weekly) PUVA ( n = 9) or...
Objective The aim of the study was to assess efficacy and safety fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 CLE, refractory topical corticosteroids, were included. primary endpoint evaluation FAEs after 24 weeks treatment as assessed by Revised Cutaneous Lupus Disease Area Severity Index (RCLASI). Results Compared baseline, significant improvement mean total RCLASI activity score...
Sézary syndrome (SS) and mycosis fungoides (MF), 2 types of cutaneous T-cell lymphoma, cause significant morbidity adversely affect patients' quality life (QoL). The present study assessed the QoL measurement changes in patients receiving mogamulizumab versus vorinostat. A multicenter phase III trial was conducted with stage IB-IV MF/SS ≥ 1 failed systemic therapy. measures included Skindex-29 Functional Assessment Cancer Therapy-General. symptoms, function, subdomains were longitudinally...
Glucocorticoids (GCs) are used as first-line therapies for generalized suppression of inflammation (e.g., allergies or autoimmune diseases), but their long-term use is limited by severe side effects. Our previous work revealed that GCs induced a stable anti-inflammatory phenotype in monocytes, the GC-stimulated monocytes (GCsMs) we exploited targeted GC-mediated therapeutic We demonstrate GCsMs interact with T cells suppressing proliferation, well cytokine release CD8(+) and, especially,...